These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 20627979)

  • 1. Prospective cohort study in high responder oocyte donors using two hormonal stimulation protocols: impact on embryo aneuploidy and development.
    Rubio C; Mercader A; Alamá P; Lizán C; Rodrigo L; Labarta E; Melo M; Pellicer A; Remohí J
    Hum Reprod; 2010 Sep; 25(9):2290-7. PubMed ID: 20627979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A prospective, randomized, controlled trial comparing three different gonadotropin regimens in oocyte donors: ovarian response, in vitro fertilization outcome, and analysis of cost minimization.
    Melo M; Bellver J; Garrido N; Meseguer M; Pellicer A; Remohí J
    Fertil Steril; 2010 Aug; 94(3):958-64. PubMed ID: 19931075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of recombinant versus human derived follicle stimulating hormone on the oocyte and embryo quality in IVF-ICSI cycles: Randomised, controlled, multi-centre trial.
    Abate A; Nazzaro A; Salerno A; Marzano F; Pavone Cossut MR; Perino M
    Gynecol Endocrinol; 2009 Aug; 25(8):479-84. PubMed ID: 19572228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early ovarian hyperstimulation syndrome is completely prevented by gonadotropin releasing-hormone agonist triggering in high-risk oocyte donor cycles: a prospective, luteal-phase follow-up study.
    Bodri D; Guillén JJ; Trullenque M; Schwenn K; Esteve C; Coll O
    Fertil Steril; 2010 May; 93(7):2418-20. PubMed ID: 19800620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose of recombinant FSH and oestradiol concentration on day of HCG affect embryo development kinetics.
    Muñoz M; Cruz M; Humaidan P; Garrido N; Pérez-Cano I; Meseguer M
    Reprod Biomed Online; 2012 Oct; 25(4):382-9. PubMed ID: 22877941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Milder ovarian stimulation for in-vitro fertilization reduces aneuploidy in the human preimplantation embryo: a randomized controlled trial.
    Baart EB; Martini E; Eijkemans MJ; Van Opstal D; Beckers NG; Verhoeff A; Macklon NS; Fauser BC
    Hum Reprod; 2007 Apr; 22(4):980-8. PubMed ID: 17204525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Corifollitropin alfa in a long GnRH agonist protocol: proof of concept trial.
    Fatemi HM; Oberyé J; Popovic-Todorovic B; Witjes H; Mannaerts B; Devroey P
    Fertil Steril; 2010 Oct; 94(5):1922-4. PubMed ID: 20149360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel protocol of ovulation induction with delayed gonadotropin-releasing hormone antagonist administration combined with high-dose recombinant follicle-stimulating hormone and clomiphene citrate for poor responders and women over 35 years.
    D'Amato G; Caroppo E; Pasquadibisceglie A; Carone D; Vitti A; Vizziello GM
    Fertil Steril; 2004 Jun; 81(6):1572-7. PubMed ID: 15193479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of GnRH antagonists and flareup GnRH agonists in donor oocyte cycles.
    Wei AY; Mijal KA; Christianson MS; Schouweiler CM; Lindheim SR
    J Reprod Med; 2008 Mar; 53(3):147-50. PubMed ID: 18441715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of recombinant human follicle-stimulating hormone in improving oocyte quality in assisted reproductive techniques.
    Cheon KW; Byun HK; Yang KM; Song IO; Choi KH; Yoo KJ
    J Reprod Med; 2004 Sep; 49(9):733-8. PubMed ID: 15493565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intermediate and normal sized CGG repeat on the FMR1 gene does not negatively affect donor ovarian response.
    Lledo B; Guerrero J; Ortiz JA; Morales R; Ten J; Llacer J; Gimenez J; Bernabeu R
    Hum Reprod; 2012 Feb; 27(2):609-14. PubMed ID: 22157911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Supplementation with a recombinant human chorionic gonadotropin microdose leads to similar outcomes in ovarian stimulation with recombinant follicle-stimulating hormone using either a gonadotropin-releasing hormone agonist or antagonist for pituitary suppression.
    Cavagna M; Maldonado LG; de Souza Bonetti TC; de Almeida Ferreira Braga DP; Iaconelli A; Borges E
    Fertil Steril; 2010 Jun; 94(1):167-72. PubMed ID: 19342035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ovarian response and pregnancy outcome in poor-responder women: a randomized controlled trial on the effect of luteinizing hormone supplementation on in vitro fertilization cycles.
    Barrenetxea G; Agirregoikoa JA; Jiménez MR; de Larruzea AL; Ganzabal T; Carbonero K
    Fertil Steril; 2008 Mar; 89(3):546-53. PubMed ID: 17531989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ovarian stimulation protocols based on follicle-stimulating hormone glycosylation pattern: impact on oocyte quality and clinical outcome.
    Selman H; Pacchiarotti A; El-Danasouri I
    Fertil Steril; 2010 Oct; 94(5):1782-6. PubMed ID: 19939369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prospective trial comparing oocyte donor ovarian response and recipient pregnancy rates between suppression with gonadotrophin-releasing hormone agonist (GnRHa) alone and dual suppression with a contraceptive vaginal ring and GnRH.
    Martínez F; Boada M; Coroleu B; Clua E; Parera N; Rodríguez I; Barri PN
    Hum Reprod; 2006 Aug; 21(8):2121-5. PubMed ID: 16632462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of poor responders: can outcomes be improved with a novel gonadotropin-releasing hormone antagonist/letrozole protocol?
    Schoolcraft WB; Surrey ES; Minjarez DA; Stevens JM; Gardner DK
    Fertil Steril; 2008 Jan; 89(1):151-6. PubMed ID: 17482177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short coasting of 1 or 2 days by withholding both gonadotropins and gonadotropin-releasing hormone agonist prevents ovarian hyperstimulation syndrome without compromising the outcome.
    Moon HS; Joo BS; Moon SE; Lee SK; Kim KS; Koo JS
    Fertil Steril; 2008 Dec; 90(6):2172-8. PubMed ID: 18439601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extended induction of ovulation by human menopausal gonadotropins and a gonadotropin-releasing hormone analog in high responders for in vitro fertilization and oocyte donation.
    Amit A; Yaron Y; Azem F; Peyser MR; David MP; Lessing JB
    J Reprod Med; 1995 Sep; 40(9):633-7. PubMed ID: 8576879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum luteinizing hormone in patients undergoing ovarian stimulation with gonadotropin-releasing hormone antagonists and recombinant follicle-stimulating hormone and its relationship with cycle outcome.
    Bosch E; Escudero E; Crespo J; Simón C; Remohí J; Pellicer A
    Fertil Steril; 2005 Nov; 84(5):1529-32. PubMed ID: 16275263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized, comparative pilot study of pituitary suppression with depot leuprorelin versus cetrorelix acetate 3 mg in gonadotropin stimulation protocols for oocyte donors.
    Martínez F; Clua E; Santmartí P; Boada M; Rodriguez I; Coroleu B
    Fertil Steril; 2010 Nov; 94(6):2433-6. PubMed ID: 20430379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.